Equity · Healthcare
ALNY
Alnylam Pharmaceuticals, Inc. · NasdaqGS
The line runs $289.28 on 11 June through $260 on 8 September, on a scale from $200 to $350. Days the market did not trade hold the previous close, flat.
The chart above plots the price of ALNY over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $289.28 on 11 June 2026 through $260 on 8 September 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 9, 2026
ALNY insider trades
ALNY has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 1 June 2026.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 16 compensation filings in this window. The figures above count all of them.
ALNY reported financials
ALNY reported revenue of $3.7B for the fiscal year ended 31 Dec 2025. Net income over the same period was $313.7M.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
ALNY earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
ALNY institutional holders
10 of the 45 institutional funds we track reported a ALNY position for the quarter ended 30 Jun 2026 — a combined $1.5B; the latest of those filings landed 02 Sep 2026.
Source: SEC EDGAR 13F filings
ALNY fails-to-deliver
On 12 Aug 2026, 2 shares of ALNY failed to deliver (about $442).
Source: SEC fails-to-deliver (CNS) data